World Health Organization in its 2019 statistics has reported that out of the 17 million premature deaths 82 % of the deaths were from the lower and middle income countries, and 37 % of these were due to cardiovascular diseases. The risk factors identified to be associated to the worsening of the disease etiology related to cardiac complications are, binge drinking, smoking, obesity and type 2 diabetes. It is noteworthy to understand that there are no symptoms in the blood vessel diseases, a heart attack or stroke are considered as warning for the underlying diseases. Drug eluting stents finds importance in the cardiovascular complications as it is a minimally invasive surgical procedure, broadens the constricted blood vessels, and is useful in prolonging the life of the patient.

Polymer based coating and polymer free coating has been included in the product segment. Polymer based coating is further sub segmented as non-biodegradable and biodegradable polymer based coatings. Polymer free coating comprises of micro porous surface, microstructured surface, slotted tubular surface and nanoporous surface. The application segment comprises of periphery artery disease and coronary artery disease. With respect to the scope of report market estimation and forecast for the duration 2019-2029 is included in the report.

Market sizing and data forecast for the country cross sectional has been covered in the scope of the report.

Porter’s five forces model has been included in the scope of the report which give a holistic view regarding the market dynamics prevalent in the drug eluting stents market. Competitive landscape is a very useful study which gives insights regarding the competition faced by the major companies trying to gain a strong foothold in the drug eluting stents market.  The major players in global Drug Eluting Stents market are Stentys, Abbott Laboratories, Inc., Biosensors International Group, Biotronik, Boston Scientific Corporation, Cook Medical, Lepu Medical Technology, Medtronics Plc, Terumo Medical Corporation and Shandong JW Medical Systems.

Atherosclerotic plaques comprises of cholesterol, fat, calcium and other inflammatory substances present in the blood usually builds up in the arteries. It is of prime importance to understand the fatal outcomes of untreated atherosclerotic plaques which may lead to stroke, heart attack, and death in severe cases. Polymer free coating stents shows market domination as it has faster drug elution rate. Microporous surface stent is gaining tremendous demand due to its reduction in the in-stent restenosis. Nanoporous surface has excellent features such as higher drug loading capacity and hence drives the polymer free coating stents market.  Polymer based coating are gaining good momentum as it is useful in addressing the problems of local inflammation and neointima hyperplasia by suppressing them and also providing sustained and controlled drug release for a longer period of time. The major players in drug eluting stents market are Abbott Laboratories, Inc., Biosensors International Group, Biotronik, Boston Scientific Corporation, Cook Medical, Lepu Medical Technology, Medtronics Plc, Terumo Medical Corporation, Shandong JW Medical Systems and Stentys.

According to the World Health Organization cardiovascular diseases are one of the prime causes of global deaths accounting for 17.7 million deaths each year which represents 31 % of the deaths worldwide. Increased consumption of fast food, profound smoking habit, obesity and stress accounts for the morbidity due to stroke, and heart attacks. It is noteworthy that 80 % of all the cardiovascular deaths are due to either stroke or heart attacks which occur due to narrowing of arteries due to atherosclerotic plaques causing hypertension and reduced supply of oxygen. Coronary artery disease is most prevalent condition in cardiovascular complications due to increasing number of patients suffering with type-2 diabetes, excessive alcohol consumption, high levels of C reactive proteins, and consumption of poor diet deficient in vitamin E, D and C. Peripheral artery disease is precipitating at a faster pace as the blockage of arteries in the proximities causes claudication while walking and climbing, erectile dysfunction in men, and sores and wounds of the feet that heal poorly.

North American dominance is related to the rising prevalence of cardiovascular disease. The American Heart Association in its Heart Disease and Strokes Statistics 2021 has reported that cardiovascular disease is responsible for the deaths of around 800,000 U.S. citizens which is equivalent to one in every three deaths. Sedentary lifestyle, rising consumption of saturated food products contributes towards growth of North America drug eluting stents market. The European market is driven by the rising prevalence of type 2 diabetes and obesity. The presence of pharmaceutical companies manufacturing drug eluting stents represent Europe’s market growth for drug eluting stents. Presence of baby boomer population with cardiovascular complications, increasing public health awareness, and supportive regulatory environment for drug eluting stents drive the Asia Pacific Market. Enhanced Government spending in establishment of developed healthcare centers and foreign direct investment by healthcare medical device manufacturers will have an impressive growth for drug eluting stents market in the Middle East and Africa and Latin America.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Drug Eluting Stents market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Drug Eluting Stents market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Drug Eluting Stents market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Drug Eluting Stents market?
• Which is the largest regional market for Drug Eluting Stents market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Drug Eluting Stents market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Drug Eluting Stents market worldwide?